Notice of Results

RNS Number : 6523J

EKF Diagnostics Holdings PLC

25 August 2021

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Notice of Results

Investor briefing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, w ill announce its interim results for the six months ended 30 June 2021 on Tuesday 14 September 2021.

Investor briefing

EKF Diagnostics will be hosting a live online presentation open to all investors on Wednesday 15 September 2021 at 5.15 pm (BST), via video conference call. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email   [e-mail] .  

EKF Diagnostics Holdings plc		www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman		Tel: [phone]
Julian Baines, CEO
Richard Evans, FD & COO
Singer Capital Markets		Tel: [phone]
Aubrey Powell / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

END

 

 

NORFZGZRKDZGMZM